We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Invitrogen and Chroma Therapeutics Extend Kinase Screening Partnership
News

Invitrogen and Chroma Therapeutics Extend Kinase Screening Partnership

Invitrogen and Chroma Therapeutics Extend Kinase Screening Partnership
News

Invitrogen and Chroma Therapeutics Extend Kinase Screening Partnership

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Invitrogen and Chroma Therapeutics Extend Kinase Screening Partnership"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Invitrogen Corporation has announced an extension to its partnership with Chroma Therapeutics Ltd. As a part of this partnership, Invitrogen will use its SelectScreen™ platform to perform biochemical screening on Chroma’s multi-targeted kinase inhibitors at Invitrogen’s Paisley, Scotland, UK, facility. Financial details of the collaboration were not disclosed.

Invitrogen’s SelectScreen™ profiling and screening service integrates enzyme collections and cell-lines with state-of-the-art bioassay technologies to accelerate drug discovery programs.

The SelectScreen™ collection of assays has been assembled to address therapeutically relevant targets, phylogenetic diversity and key signaling pathways, all of which are of interest to companies developing kinase inhibiting compounds. Invitrogen offers compound profiling services through laboratories located in Madison, Wisconsin, USA, and Paisley, Scotland.

“Our partnership with Chroma Therapeutics demonstrates the value they find in our kinase biology expertise, as well as the high quality data they receive with a very rapid turnaround,” commented Nick Ecos, vice president and general manager of Invitrogen’s Discovery Sciences business. “Time is essential to our collaborators and our locations in the US and UK are ideally located for a rapid turnaround.”

Advertisement